AmeRuss's competitive advantage derives from flexibility and focus on cost sensitivity - both vital in today's new drug and device development marketplace. In addition, AmeRuss's CRA teams consist of individuals with advanced educational degrees (most are MDs) who bring medical knowledge and expertise to the trial management and monitoring process and accelerate trial completion most efficiently and effectively.
AmeRuss's strategic advantage in Russia relates to its alliance with the reputable SHAG Company, a premier consortium of functional groups for the provision and sale of innovative medical and analytical devices and pharmaceuticals to Russia and other regional countries. An equivalent cooperative bond exists with the Implanta group of companies, the Russian market leaders in the implantable cardiovascular device space. These alliances enable AmeRuss's relationships with numerous specialty centers of the Russian Academy of Medical Sciences (RAMS) with extensive clinical research experience. AmeRuss thereby has access to the top specialty leadership within the centralized Russian healthcare system. Networks of additional clinical sites throughout Russia affiliated with these centers represent a scalable base of investigator sites. The resulting AmeRuss network can capacitate the demands of very large pharmaceutical and medical device trials, making AmeRuss a sponsor's best option to leverage the advantages in Russia, Belarus, and Ukraine.
AmeRuss adheres to values of professionalism, leadership, and reliability shared by the SHAG Company and the Implanta Group, both recognized leaders in providing the latest medical technology to all regions of the Russian Federation. These industry pace-setters have chosen synergy with AmeRuss to provide clinical research opportunities from abroad to the same key opinion leaders and institutions that are decision makers for SHAG and Implanta.
AmeRuss Compassionate Care Initiative
AmeRuss's overarching principle in accomplishing its business goals is first to provide the highest quality care to the subjects/patients in any trial in which we participate. In doing so, we "put the subject/patient first". Our core competency focuses on the goal of managing and executing trials in the most efficient and effective ways possible. However, these goals are subservient to ensuring the best medical interests of subjects/patients. By adhering to this standard, the rest of our goals will be achieved.
AmeRuss pursues an active interest in assisting and facilitating Compassionate Care programs at every opportunity. Our in-house expertise and experience can help sponsors and other organizations to realize these social imperatives. Consider AmeRuss to assist your firm in these objectives throughout our region.
